All In Biotech

NDA 021184 · Chartwell Rx

Tazorac

Tazarotene · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Sep 29, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

61

15 Phase 3, 0 recruiting

FAERS reports

945

382 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2026.

TAZORAC ® Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) TAZORAC Cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis TAZORAC ® (tazarotene) Cream, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris TAZORAC (tazarotene) Cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.

Mechanism: Tazarotene is a retinoid prodrug which is converted to its active form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings is unknown.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TAZORAC · TAZAROTENE 0.1% · CREAM, TOPICAL · Prescription · TE AB
  • AVAGE · TAZAROTENE 0.1% · CREAM, TOPICAL · Prescription · TE AB
  • TAZORAC · TAZAROTENE 0.05% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tazarotene" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective94
  • off label use74
  • pain52
  • headache51
  • erythema47
  • pruritus44
  • skin exfoliation42
  • rash41
  • psoriasis40
  • diarrhoea36
  • nausea34
  • acne33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200529
200612
200713
200817
20098
201043
201130
201275
201347
201424
201540
201688
201757
201868
201967
202037
202125
202240
202388
202446
202538
202642

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tazorac (Tazarotene)

2024 spending

$1.4M

Beneficiaries

770

1,572 claims

Per beneficiary

$1,858

$15.76 per unit

View as table
YearSpending
2020$1,267,925
2021$2,083,194
2022$2,067,405
2023$1,699,875
2024$1,430,458

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 171 on PubMed

Sponsor: Chartwell Rx · Also marketed as Avage

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.